Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

http://www.wikidata.org/entity/Q37380454

about

A Perspective of Immunotherapy for Prostate Cancer Advances in immunotherapy for melanoma The Utilization of the Immune System in Lung Cancer Treatment: Beyond Chemotherapy The role of immune checkpoint inhibition in the treatment of ovarian cancer Advances in Cancer Immunotherapy in Solid Tumors Adverse Events Associated with Immune Checkpoint Blockade in Patients with Cancer: A Systematic Review of Case Reports Ipilimumab: from preclinical development to future clinical perspectives in melanoma.New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis.Checkpoint inhibitors in hematological malignancies Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis Cost-Effectiveness of Immune Checkpoint Inhibition in BRAF Wild-Type Advanced Melanoma.Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood.Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy Colonic ulcerations may predict steroid-refractory course in patients with ipilimumab-mediated enterocolitis.Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.Atezolizumab for the treatment of non-small cell lung cancer.A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity.Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.Checkpoint inhibition and melanoma: Considerations in treating the older adult.Immunotherapy of advanced renal cell carcinoma: Current and future therapies.Targeted agents and immunotherapies: optimizing outcomes in melanoma.Targeted Therapies for Melanoma Brain Metastases.Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer.Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma.Ipilimumab in melanoma.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.Cutaneous Complications of Targeted Melanoma Therapy.Genomic Approaches to Understanding Response and Resistance to Immunotherapy.Cancer immunotherapy in patients with preexisting autoimmune disorders.Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors.Development of CAR T cells designed to improve antitumor efficacy and safety.Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review.Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities.

P2860

Q26741277-6C6C8034-BC26-4A17-AE24-F124BFB812A1 Q26768558-888CD50A-9765-47BC-B0AC-5F998D6C5A76 Q28066568-AFB8B2E2-7321-4336-A310-37F506C848F5 Q28077924-4F166748-3D25-47C3-A88A-73326C349186 Q28080113-76212618-465B-4607-91D1-EC68B78BF70F Q28553328-BC6B2D79-4EF0-4A46-9784-0819CE4E5550 Q30240751-F5E05D8C-0FF6-4B4E-8614-6F4D9133F483 Q33564645-05E2F501-43AC-436F-A0B5-011B42A5ACFB Q33607108-29C5F899-9127-47C4-A756-22BBCB98A409 Q33651495-F97F3530-D423-4A76-A6A5-CA73429F9D3F Q33813378-5D78B16B-6B4B-4446-818E-E163326816D2 Q36286084-48B0DB1E-7BE3-4D99-988B-FA141734783E Q36343040-61C5DFAB-69BD-4AC0-83E6-310E93E60B59 Q36413957-5B84EAA5-030E-40A7-AE01-F0D54A780B3C Q36759340-E93DE86F-67D2-4162-AD11-6DC0EAB3DBD8 Q36866154-0BF49A64-CC51-4FA2-9DDF-CBA3849E8FF2 Q36951236-6A1D3CA6-7EA7-4BB0-BD27-09564837044C Q37131014-408A7ADA-581E-4432-861F-D65130F9E92F Q37224609-460531C0-3FC5-4AA1-876F-A87F5D535427 Q37629874-28DCE155-80B3-42C0-AA17-4287B6F83A4A Q37714359-67B7DA9A-675A-4A0B-B100-545E23649D41 Q38586991-6B21175E-5138-4A69-B706-5B1690AA99C1 Q38675969-61C3717B-9F46-4C0F-B906-28E9B5920A0E Q38713958-944B4BBC-D07A-4A1E-9C13-85DE54AC25A9 Q38775281-199E6351-2582-4831-ACC6-6ADEB6115BF7 Q38785125-B0F6EE1A-F55B-4F3B-B208-E10970DB170B Q38834167-64160C95-F3AC-4B08-9D7B-FF086131039B Q38856722-CF62ABF7-0E65-41D5-9D62-86DBE4404396 Q38857040-BEEEA63F-DAA6-409D-ABF7-70349F72A150 Q38870763-0816F5F1-2685-4EDB-B8D1-76B7A4D440F3 Q38884560-1051AC88-CD0C-4D26-915C-2F339BBDABD8 Q38893697-2A3349C6-6DB8-4FE2-ADCD-4A85C67CACA9 Q38930084-C03E395E-F8E7-4CD3-A276-9447167DE07B Q38958844-8A328B9D-247D-45CF-B494-A1ADC54B32DD Q38971262-8B7B2E09-CA0E-4618-88EF-620B3EF5E526 Q38978399-1A624DE0-1EBF-44D6-A67F-238D87E76963 Q39009781-B4A98B34-1152-44AD-99F5-50840E93D225 Q39200527-7975FD9C-A085-42A5-81D8-7A3A7A0352E6 Q39398054-04CCC59C-04A0-419E-8246-9B153790098E Q39430042-67AB1533-9757-4668-A761-E6B7B7894CD5

P2860

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Item

http://www.wikidata.org/entity/Q37380454

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center

@en

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center.

@nl

type

Item

label

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center

@en

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center.

@nl

prefLabel

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center

@en

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center.

@nl

P1476

Immune-Related Adverse Events, ...... Sloan Kettering Cancer Center

@en

P2093

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Kaitlin M Woo

http://www.w3.org/2001/XMLSchema#string

Katherine S Panageas

http://www.w3.org/2001/XMLSchema#string

Margaret K Callahan

http://www.w3.org/2001/XMLSchema#string

Mark A Dickson

http://www.w3.org/2001/XMLSchema#string

Michael A Postow

http://www.w3.org/2001/XMLSchema#string

Nelly G Adel

http://www.w3.org/2001/XMLSchema#string

Paul B Chapman

http://www.w3.org/2001/XMLSchema#string

Richard D Carvajal

http://www.w3.org/2001/XMLSchema#string

Sandra P D'Angelo

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Management of immune-related adverse events and kinetics of response with ipilimumab.

Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab.

P304

3193-3198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2015.60.8448

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Parisa Momtaz

Troy Z Horvat

P577

2015-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26282644

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

patient

Ipilimumaab

P932

5087335

http://www.w3.org/2001/XMLSchema#string

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

about

P2860

P2860

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932